From our experience with the adalimumab biosimilar launches in 2023, we learned several lessons. One is that our existing pharmacy benefit manager (PBM)–driven rebate system dictates not only coverage but utilization. Second is that employers must flex their leverage muscle if they want full pass-through of rebates and full transparency regarding PBM-based rebates and fees. … Continue reading Employer Survey Sees Further Demand for PBM Transparency